Real time dynamic imaging and current targeted therapies in the war on cancer: A new paradigm

Theranostics

Volumn 3, Issue 6, 2013, Pages 437-447

  Paulmurugan, Ramasamy ^a   Oronsky, Bryan ^b   Brouse, Chad F ^c   Reid, Tony ^d   Knox, Susan ^e   Scicinski, Jan ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RadioRx Inc   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Cancer therapy; Drug delivery; Imaging; MicroRNA

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE; [2 (2 NITRO 1[H] IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE]; ANTINEOPLASTIC AGENT; ANTIOXIDANT; AXITINIB; CARBON MONOXIDE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MICRORNA; OXALIPLATIN; RRX 001; TOXIC SUBSTANCE; TRACER; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; WATER;

ADVANCED CANCER; ANTIOXIDANT ACTIVITY; BIOTECHNOLOGY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER STAGING; CANCER THERAPY; CELL DIVISION; CELL KILLING; CELL SPECIFICITY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCED ULTRASOUND; CONTRAST ENHANCEMENT; DATA ANALYSIS; DETOXIFICATION; DRUG DELIVERY SYSTEM; DRUG TREATMENT FAILURE; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; ELASTOGRAPHY; HEALTH CARE FACILITY; HOMEOSTASIS; HUMAN; INFORMATION PROCESSING; KIDNEY CARCINOMA; LETHALITY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL SOCIETY; METASTATIC COLORECTAL CANCER; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; ONCOLOGY; PANCREAS CANCER; PATIENT CARE; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYLOGENY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; REAL TIME DYNAMIC IMAGING; REVIEW; TARGET CELL; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; ULTRASOUND;

CANCER; CANCER THERAPY; DRUG DELIVERY.; IMAGING; MICRORNA;

HUMANS; INDIVIDUALIZED MEDICINE; MICRORNAS; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84883184920     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.5658     Document Type: Review

References (106)

1. Ilivitzki A, Radan L, Ben-Arush M, Israel O, Ben-Barak A. Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease-added value of low-dose CT. Pediatr Radiol 2013;43: 86-92.
2. Ding XP, et al. Feasibility of Shrinking Field Radiation Therapy through 18F-FDG PET/CT after 40 Gy for Stage III Non-Small Cell Lung Cancers. APJCP 2012;13: 319-323.
3. Bartsevich VV, Juliano RL. Regulation of the MDR1 gene by transcriptional repressors selected using peptide combinatorial libraries. Mol Pharmacol 2000;58: 1-10.
4. Marthinet E, Divita G, Bernaud J, Rigal D, Baggetto LG. Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter. Gene Ther 2000;7: 1224-1233.
5. Tiberghien F, Kurome T, Takesako K, Didier A, Wenandy T, Loor F. Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter. J Med Chem 2000;43: 2547-2556.
6. Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, Kelly KM. Antioxidants and cancer therapy: a systematic review. J Clin Oncol 2004;22: 517-528.
7. Oronsky BT, Reid T, Knox SJ, Scicinski JJ. The scarlet letter of alkylation: a mini review of selective alkylating agents. Transl Oncol 2012;5: 226-229.
8. Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox SJ. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res 2012;72: 2600-2608.
9. Scicinski J, et al. Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent. Drug Metab Dispos 2012;40: 1810-1816.
10. Taneja SS. Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. J Urol 2012;188: 412-413.
11. Kenney PA, Wood CG. Words of wisdom. Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Eur Urol 2012;62: 182-183.
12. Rini BI, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378: 1931-1939.
13. Solanki AA, et al. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol 2012;7: 216.
14. Matsumoto I, et al. Usefulness of fluorine-18 fluorodeoxyglucose- positron emission tomography in management strategy for thymic epithelial tumors. Ann Thorac Surg 2013;95: 305-310.
15. Li X, et al. An algorithm for longitudinal registration of PET/CT images acquired during neoadjuvant chemotherapy in breast cancer: preliminary results. EJNMMI Res 2012;2: 62.
16. Kim HS, Kim CK, Park BK, Huh SJ, Kim B. Evaluation of therapeutic response to concurrent chemoradiotherapy in patients with cervical cancer using diffusion-weighted MR imaging. J Magn Reson Imaging 2013;37: 187-193.
17. Saito N, et al. Posttreatment CT and MR imaging in head and neck cancer: what the radiologist needs to know. Radiographics 2012;32: 1261-1282.
18. Hylton NM, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology 2012;263: 663-672.
19. Mercier L, Del Maestro RF, Petrecca K, Araujo D, Haegelen C, Collins DL. Online database of clinical MR and ultrasound images of brain tumors. Med Phys 2012;39: 3253-3261.
20. Smyslenova MV, Tarasenko SV, Shipkova TP, Rudnev AI, Faskhutdinov DK. [Capabilities of ultrasound study in the differential diagnosis of neoplasms of the major salivary glands]. Vestn Rentgenol Radiol 2012;: 8-11.
21. Yang X, et al. Ultrasound GLCM texture analysis of radiation-induced parotid-gland injury in head-and-neck cancer radiotherapy: an in vivo study of late toxicity. Med Phys 2012;39: 5732-5739.
22. Pauwels EK, Coumou AW, Kostkiewicz M, Kairemo K. [F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/ Computed Tomography Imaging in Oncology: Initial Staging and Evaluation of Cancer Therapy. Med Princ Pract. 2013
23. Abramyuk A, Appold S, Zophel K, Baumann M, Abolmaali N. Modification of staging and treatment of head and neck cancer by FDG-PET/CT prior to radiotherapy. Strahlenther Onkol 2013.
24. Lodge MA, Badawi RD, Gilbert R, Dibos PE, Line BR. Comparison of 2-dimensional and 3-dimensional acquisition for 18F-FDG PET oncology studies performed on an LSO-based scanner. J Nucl Med 2006;47: 23-31.
25. Hawkins RA, Hoh CK. PET FDG studies in oncology. Nucl Med Biol 1994;21: 739-747.
26. Sauter AW, et al. Correlation between [(18)F]FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2013.
27. Malle P, Sorschag M, Gallowitsch HJ. FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours. Wien Med Wochenschr 2012;162: 423-429.
28. Bertagna F, Bosio G, Orlando E, Biasiotto G, Giubbini R. Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST). Nucl Med Rev Cent East Eur 2010;13: 76-80.
29. Asselin MC, O'Connor JP, Boellaard R, Thacker NA, Jackson A. Quantifying heterogeneity in human tumours using MRI and PET. Eur J Cancer 2012;48: 447-455.
30. Evans SM, et al. EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2006;64: 922-927.
31. Ziemer LS, et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med Mol Imag 2003;30: 259-266.
32. Laking GR, West C, Buckley DL, Matthews J, Price PM. Imaging vascular physiology to monitor cancer treatment. Crit Rev Oncol Hematol 2006;58: 95-113.
33. Langen KJ, et al. 3-[123I]iodo-alpha-methyltyrosine and [methyl- 11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med 1997;38: 517-522.
34. Ter-Pogossian MM. Basic principles of computed axial tomography. Semin Nucl Med 1977;7: 109-127.
35. De Cecco CN, et al. Dual-energy CT: oncologic applications. AJR Am J Roentgenol 2012;199: S98-S105.
36. Kadowaki K, et al. Helical CT imaging of gastric cancer: normal wall appearance and the potential for staging. Radiat Med 2000;18: 47-54.
37. Kim EE. Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology. Int J Gynecol Cancer 2004;14: 12-22.
38. Bowen SR, et al. Challenges and opportunities in patient-specific, motion- managed and PET/CT-guided radiation therapy of lung cancer: review and perspective. Clin Transl Med 2012;1: 18.
39. Min CH, et al. Clinical Application of In-Room Positron Emission Tomography for In Vivo Treatment Monitoring in Proton Radiation Therapy. Int J Radiat Oncol Biol Phys. 2013.
40. Paushter DM, Modic MT, Borkowski GP, Weinstein MA, Zeman RK. Magnetic resonance. Principles and applications. Med Clin North Am 1984;68: 1393-1421.
41. Chilton HM, Ekstrand KE. Principles and applications of nuclear magnetic resonance imaging. Am J Hosp Pharm 1984;41: 763-768.
42. Moon M, Cornfeld D, Weinreb J. Dynamic contrast-enhanced breast MR imaging. Magn Reson Imaging Clin N Am 2009;17: 351-362.
43. Morakkabati-Spitz N, Schild HH, Leutner CC, von Falkenhausen M, Lutterbey G, Kuhl CK. Dynamic contrast-enhanced breast MR imaging in men: preliminary results. Radiology 2006;238: 438-445.
44. Tunariu N, Kaye SB, Desouza NM. Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?. Br J Cancer 2012;106: 619-628.
45. Leach MO, et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol 76 Spec No 2003;1: S87-91.
46. Yankeelov TE, Gore JC. Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples. Curr Med Imaging Rev 2009;3: 91-107.
47. Rehman S, Jayson GC. Molecular imaging of antiangiogenic agents. Oncologist 2005;10: 92-103.
48. Quaia E. Assessment of tissue perfusion by contrast-enhanced ultrasound. Eur Radiol 2010;21: 604-615.
49. Delorme S, Krix M. Contrast-enhanced ultrasound for examining tumor biology. Cancer Imaging 2006;6: 148-152.
50. Wilson SR, Burns PN. Microbubble-enhanced US in body imaging: what role?. Radiology 2010;257: 24-39.
51. Krix M, et al. Quantification of perfusion of liver tissue and metastases using a multivessel model for replenishment kinetics of ultrasound contrast agents. Ultrasound Med Biol 2004;30: 1355-1363.
52. Jang HJ, Yu H, Kim TK. Contrast-enhanced ultrasound in the detection and characterization of liver tumors. Cancer Imaging 2009;9: 96-103.
53. Pysz MA, Foygel K, Rosenberg J, Gambhir SS, Schneider M, Willmann JK. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology 2010;256: 519-527.
54. Willmann JK, et al. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology 2008;248: 936-944.
55. Sporea I, Sirli R, Popescu A, Danila M. Acoustic Radiation Force Impulse (ARFI)--a new modality for the evaluation of liver fibrosis. Med Ultrason 2010;12: 26-31.
56. Friedrich-Rust M, et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009;252: 595-604.
57. Nightingale K, Soo MS, Nightingale R, Trahey G. Acoustic radiation force impulse imaging: in vivo demonstration of clinical feasibility. Ultrasound Med Biol 2002;28: 227-235.
58. Beretta GD, et al. FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials. Med Oncol 2013;30: 486.
59. Sanchez-Rovira P, et al. Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response. Clin Transl Oncol. 2013.
60. Patson B, R BC, Olszanski AJ. Pharmacokinetic evaluation of axitinib. EXPERT OPIN DRUG MET 2012;8: 259-270.
61. Sharma S, et al. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol 2009;21: 297-304.
62. Hoh C, et al. Axitinib inhibition of [18F] fluorothymidine (FLT) uptake in patients (pts) with colorectal cancer (CRC): Implications for cytotoxic chemotherapy combinations. J Clin Oncol 2011;29: abstr359.
63. Bendell J, et al. Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2011;29: abstr478.
64. Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox S. Dintroazetidines are a Novel Class of Anticancer Agents and Hypoxia- activated Radiation Sensitizers Developed from Highly Energetic Materials. Cancer Res 2012;72: 2600-2608.
65. Scicinski J, et al. Disposition of 14C-RRx-001 in Rats after A Single Intravenous Administration and in Blood from Rats, Dogs, Monkeys, and Humans. In 17th North American Regional ISSX Meeting, P81, Atlanta, GA. 2011.
66. Fens MHAM, et al. NO or No NO, Increased Reduction of Nitrite to Nitric Oxide by Modified Red Blood Cells. Blood (ASH Annual Meeting Abstracts) 2011;118: 2125.
67. Foyer CH, Noctor G. Redox homeostasis and antioxidant signaling: a metabolic interface between stress perception and physiological responses. Plant Cell 2005;17: 1866-1875.
68. Cullinan SB, Diehl JA. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J Biol Chem 2004;279: 20108-20117.
69. Li Y, Jaiswal AK. Human antioxidant-response-element-mediated regulation of type 1 NAD(P)H:quinone oxidoreductase gene expression. Effect of sulfhydryl modifying agents. Eur J Biochem 1994;226: 31-39.
70. Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci U S A 1996;93: 14960-14965.
71. Nioi P, Nguyen T, Sherratt PJ, Pickett CB. The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. Mol Cell Biol 2005;25: 10895-10906.
72. Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A 1994;91: 9926-9930.
73. Yamamoto T, et al. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 2008;28: 2758-2770.
74. Sekhar KR, Rachakonda G, Freeman ML. Cysteine-based regulation of the CUL3 adaptor protein Keap1. Toxicol Appl Pharmacol 2010;244: 21-26.
75. Bloom DA, Jaiswal AK. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element- mediated NAD(P)H:quinone oxidoreductase-1 gene expression. J Biol Chem 2003;278: 44675-44682.
76. DeNicola GM, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011;475: 106-109.
77. Kong Q, Lillehei KO. Antioxidant inhibitors for cancer therapy. Med Hypotheses 1998;51: 405-409.
78. Sharifi N. Commentary: Antioxidants for cancer: new tricks for an old dog?. Oncologist 2009;14: 213-215.
79. Yu F, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131: 1109-1123.
80. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 2006;29: 903-906.
81. Johnson SM, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120: 635-647.
82. Saito Y, et al. MicroRNAs in Hepatobiliary and Pancreatic Cancers. Front Genet 2011;2: 66.
83. Jiang S, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010;70: 3119-3127.
84. Jing Z, Nan KJ, Hu ML. Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma. World J Gastroenterol 2005;11: 1910-1916.
85. Wang XF, et al. MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. J Cancer Res Clin Oncol 2012;138: 573-584.
86. Xu Y, et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 2011;310: 160-169.
87. Hatziapostolou M, et al. An HNF4alpha-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 2011;147: 1233-1247.
88. Kutanzi KR, Yurchenko OV, Beland FA, Checkhun VF, Pogribny IP. MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics 2011;2: 171-185.
89. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007;23: 175-205.
90. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120: 15-20.
91. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012;3: 1.
92. Zhang G, Wang Q, Xu R. Therapeutics Based on microRNA: A New Approach for Liver Cancer. Curr Genomics 2010;11: 311-325.
93. Deckers R, Moonen CT. Ultrasound triggered, image guided, local drug delivery. J Control Release 2010;148: 25-33.
94. Phillips LC, Dhanaliwala AH, Klibanov AL, Hossack JA, Wamhoff BR. Focused ultrasound-mediated drug delivery from microbubbles reduces drug dose necessary for therapeutic effect on neointima formation--brief report. Arterioscler Thromb Vasc Biol 2011;31: 2853-2855.
95. Phillips LC, Klibanov AL, Wamhoff BR, Hossack JA. Localized ultrasound enhances delivery of rapamycin from microbubbles to prevent smooth muscle proliferation. J Control Release 2011;154: 42-49.
96. Wang DS, et al. Enhanced Ultrasound-Mediated Gene Delivery Using Cationic Microbubbles. Radiology; in press.
97. Miller DL, Pislaru SV, Greenleaf JE. Sonoporation: mechanical DNA delivery by ultrasonic cavitation. Somat Cell Mol Genet 2002;27: 115-134.
98. Tachibana K, Uchida T, Ogawa K, Yamashita N, Tamura K. Induction of cell-membrane porosity by ultrasound. Lancet 1999;353: 1409.
99. Brayman AA, Coppage ML, Vaidya S, Miller MW. Transient poration and cell surface receptor removal from human lymphocytes in vitro by 1 MHz ultrasound. Ultrasound Med Biol 1999;25: 999-1008.
100. Duvshani-Eshet M, Baruch L, Kesselman E, Shimoni E, Machluf M. Therapeutic ultrasound-mediated DNA to cell and nucleus: bioeffects revealed by confocal and atomic force microscopy. Gene Ther 2006;13: 163-172.
101. Kimmel E. Cavitation bioeffects. Crit Rev Biomed Eng 2006;34: 105-161.
102. Schlicher RK, Radhakrishna H, Tolentino TP, Apkarian RP, Zarnitsyn V, Prausnitz MR. Mechanism of intracellular delivery by acoustic cavitation. Ultrasound Med Biol 2006;32: 915-924.
103. Greenleaf WJ, Bolander ME, Sarkar G, Goldring MB, Greenleaf JF. Artificial cavitation nuclei significantly enhance acoustically induced cell transfection. Ultrasound Med Biol 1998;24: 587-595.
104. Chumakova OV, et al. Composition of PLGA and PEI/DNA nanoparticles improves ultrasound-mediated gene delivery in solid tumors in vivo. Cancer Lett 2008;261: 215-225.
105. Figueiredo M, Esenaliev R. PLGA Nanoparticles for Ultrasound- Mediated Gene Delivery to Solid Tumors. J Drug Deliv 2012;2012: 767839.
106. Paulmurugan R, Sekar NM, Sekar TV. Biodegradable polymer nanocarriers for therapeutic antisense microRNA delivery in living animals. Proceedings of SPIE 8232. 2012.